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BIOMARKERS FOR AGING

compounds for counteracting normal age-related cognitive
decline and/or age-related neurodegenerative diseases,

RELATED APPLICATIONS

including AlZheimer’s disease (AD) or Parkinson’s disease

(PD).
Identifying ACGs in any mammalian species therefore,
might have great therapeutic usefulness. Moreover, because

This application a Divisional of US. application Ser. No.
10/486,706, ?led Aug. 13, 2004, noW abandoned Which is a
US. National Phase under 35 USC §371 of International
Application No. PCT/US2002/ 25 607, ?led on Aug. 13, 2002,

of the Well-established homologies of most genes across

343, ?led Aug. 13, 2001, the entire contents of each of Which

mammalian species and because of the clear similarities in
patterns of brain aging and cognitive decline across species,
identi?cation in any mammal Would have human health

are hereby incorporated by reference.

implications. Furthermore, because the primary risk factor

claiming priority of US. Provisional Application No. 60/311,

for AlZheimer’s disease and Parkinson’s disease is aging

itself, therapeutic approaches developed for aging-related

STATEMENT OF GOVERNMENT INTEREST

cognitive impairment should also help ameliorate cognitive
decline from age-related neurodegenerative disease. Thus,

This invention has been made in part With government

support under grants AG04542, AG10836, AG18228 and

there is a clear need for identifying ACGs but, to date, such
genes have not been discovered for any mammal.

AG14979 from the National Institute on Aging, and by
MH59891. The government of the United States of America
may have certain rights in this invention.

Gene microarray technology provides a poWerful approach
20

FIELD OF THE INVENTION

The invention relates generally to genetic algorithms, and
more particularly to the identi?cation of gene expression

pro?le biomarkers and therapeutic targets for brain aging.

25

BACKGROUND OF THE INVENTION

for unraveling the complex processes of aging. To date, hoW
ever, its impact has been limited by statistical problems, small
sample siZes, and dif?culty in assessing functional relevance.
Moreover, studies that have examined gene expression during
brain aging using microarrays have not used sample siZes
large enough to provide adequate statistical poWer for formal
statistical testing. Lee C K et al., Nature Genetics 25: 294-297
(2000); Jiang C H et al., Proc NatlAcad Sci USA 98: 1930
1934 (2001) Therefore, even the genes they have reported to

change With aging have not been validated by accepted sta

Brain aging processes are enormously complex phenom
ena that affect multiple systems, cell types and pathWays, and
result in cognitive decline and increased risk of AlZheimer’s
disease (AD). Land?eld P W et al., J Neurobiol 23: 1247

tistical criteria.
30

The extremely large data sets generated by microarrays
pose formidable bioinformatics and resource problems that

have to date limited the impact of this powerful technology.

1260 (1992). Although several biological mechanisms have

Because of these di?iculties, most microarray studies have

been putatively linked to brain aging or AlZheimer’s disease,

relied on simple fold change comparisons in small samples.
HoWever, neither fold change analyses nor the small sample
protocols Widely used alloW the direct estimates of variance
necessary for de?ning type I error (false positives). In addi

including in?ammation, oxidative stress, Ca2+ dyshomeosta
sis (Land?eld, P W & Pitler T A, Science 226: 1089-1092
(1984); Land?eld P W et al., J Neurobiol 23: 1247-1260
(1992)), mitochondrial dysfunction and chronic exposure to
adrenal stress hormones (Land?eld P W et al., Science 214:
581-584 (1981); Porter N M & Land?eld P W, Nature Neu

35

tion, fold change criteria, by de?nition, select for large
changes. Therefore, they exhibit loW detection sensitivity
40

rosci 1: 3-4 (1998)), the speci?c mechanisms andpathWays, if
any, through Which they are linked to impaired brain function

ally important (and, therefore, tightly regulated) genes. The

are not understood.

It is Widely thought that gene expression changes contrib
ute to many aspects of declining function With aging. Finch C

E, Longevity, Senescence and the Genome, 37-42 (Univ. Chi
cago Press, Chicago, 1990). It is also thought that gene
expression changes are important for processing and storage
of memory. HoWever, not all genes that change expression in
the brain With aging are thought to be important for cognition.
Gene-expression changes that speci?cally contribute to
age-related memory decline should selectively change With
brain aging and should be correlated speci?cally With mea
sures of age-associated cognitive decline; that is, a subset of
the full set of aging-dependent genes should also correlate
With age-related cognitive decline. See, Lockhart D J & Bar
loW C, Nat Rev Neurosci 2: 63-68 (2001) and Mimics K, Nat
Rev Neurosci 2: 444-447 (2001).
If a subset of age-dependent genes also shoWs expression

patterns directly correlated With age-related memory decline,

45

inability to assign typeI error is a particularly critical problem
for microarray studies because the thousands of comparisons
of gene expression in such analyses greatly increase the
expected false positives. For example, even if group siZes
Were suf?cient for formal statistical analyses, and 5000 gene
transcripts Were each tested by t-test for differences betWeen
tWo conditions at p§0.05, the false positive rate is equal to the

50

p-value and, consequently, 5% of the 5000 tested transcripts
(250) Would be expected to be found signi?cant by chance
alone.

Although microarray studies have some important offset
ting advantages that improve statistical con?dence (e.g., co
55

regulation of genes Within a functional group), there is

increasing recognition that microarray experiments should
generally meet the same statistical standards as other biologi

60

then such a subset of “aging and cognition-related genes”
(ACGs) Would be extremely helpful as biological indexes
(“biomarkers”) for assessing or diagnosing the degree of

cal experiments or, at least, should systematically estimate
the degree of statistical uncertainty. Several strategies to
improve statistical con?dence have been developed for small
sample microarray studies, but these generally rely on indi
rect estimates of variance and/or greatly sacri?ce sensitivity

(i.e., stringent p-values).

age-related cognitive impairment in individual subjects. In
turn, the ability to measure aging-related cognitive impair
ment quantitatively is essential for discovering neW therapeu
tic targets, and developing neW strategies and pharmaceutical

(high false negatives, or type II error), and are unable to

identify the modest changes that often characterize function

Another highly important problem of microarray studies is
65

that of determining Which of the hundreds of expression
changes that may be observed are likely to be functionally
relevant. Correlation analysis is one quantitative approach to

US 7,739,056 B2
3
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linking gene expression With function, although it also

With a more stringent correlation of p<0.0l or p<0.00l)

requires relatively large sets of independent samples. Expres

betWeen brain expression and cognitive performance; and (d)
the cognitive performance in behavioral tests signi?cantly

sion-function correlations ful?ll a key prediction of a causal

relationship (i.e., that causally related variables should co

altered With aging as determined by a conventional statistical
method. The biomarkers may also correlate With a behavioral
measure of functional impairment, such as an age-related

vary) and therefore, can serve as a valuable tool for the iden

ti?cation of candidate functionally relevant genes. Nonethe
less, there have been feW correlation studies attempting to

neurodegenerative condition, including AlZheimer’s disease

link cognitive dysfunction With univariate gene expression

or Parkinson’s disease.

patterns across individual subjects, much less using the mas

The invention also provides a set of at least tWo biomarkers

sive amounts of data generated in microarray analyses.

for brain aging, Where Where the brain expression patterns of
the members of the set are signi?cantly altered With aging as

SUMMARY OF THE INVENTION

measured by a conventional statistical correlation test at a

signi?cance level of p<0.0l.
The invention provides a statistical and functional correla

The invention further provides a set of at least tWo biom

tion strategy to identify changes in cellular pathWays speci?
cally linked to impaired cognitive function With aging. The

arkers for brain aging, Where the brain expression patterns of
the members of the set are signi?cantly altered With aging as

bioinformatics and functional correlation strategy improves
the poWer of microarray analyses and provides the ability to
test Whether alterations in speci?c hippocampal pathWays are

correlated With aging-related cognitive impairment. The
invention is useful for application in large, Well-poWered
groups and for controlling type I error (false positives),
enhancing detection sensitivity (reducing type II false nega
tives) and determining Which aging changes in expression are
most closely correlated With declining brain function.
Accordingly, the invention provides a method for identify

determined by a conventional statistical method, With p<0.05
(or a more stringent correlation, such as p<0.025, p<0.0l or

p<0.00l).
20

In one example of the invention, rats in three age groups
(Young, Mid-Aged, Aged) Were characterized on tWo

memory tasks and each mammal’s hippocampal CA1 region
Was analyZed by a microarray analysis for gene expression.
These analyses identi?ed multiple groups of genes, many
25

representing pathWays With previously unrecognized rela

ing a biomarker for brain aging, Where the biomarker is a

tionships to aging and/or cognitive decline. The analysis
shoWed that for all groups, the aging changes in expression

polynucleotide or a polypeptide encoded by said polynucle

began by mid-life.

otide. The method involves ?rst obtaining a set of polynucle
otides obtained from a set of brain samples (such as hippoc
ampal samples), Where the members of the set of brain
samples Were obtained from members of a set of mammals,

30

cellular cascades that begin in mid-life and eventually impair
cognitive function and increase neuronal vulnerability. Ini
tially decreased neuronal activity and/or oxidative metabo
lism trigger separate but parallel genomic cascades in neurons

Wherein the set of mammals contains more than tWo mem

bers, With at least young, mid-aged and aged members, and
then identifying the identity and amount of the members of
the set of polynucleotides present in the brain samples. The
method then involves the steps of deleting certain non-biom
arker polynucleotides from the set of polynucleotides, testing
by a conventional statistical method (such as) for a signi?cant
effect of aging across the young, mid-aged and aged mem
bers; and correlating the identity and amount of the members
of the set of polynucleotides present in the brain samples With
cognitive performance in behavioral tests.

In one aspect of the invention, the knoWn interactions of the
identi?ed processes suggest an integrative model of speci?c

35

and glia. In neurons, the cascade results in reductions of

immediate early gene signaling, biosynthesis, synaptogen
esis and neurite remodeling. In contrast, glia undergo
increased lipid metabolism and mediate a cycle of demyeli

nation and remyelination that induces antigen presentation,
40

in?ammation, oxidative stress and extracellular restructur
ing. Intervention studies based on these ?ndings can identify
the cause and effect interactions among the complex pro
cesses of brain aging.

45

BRIEF DESCRIPTION OF THE DRAWINGS

By use of the methods of the invention, one skilled in the

genomics art can identify multiple groups of related genes,

many representing processes With previously unrecogniZed
relationships to aging and/ or cognitive dysfunction. Thus, the
invention also provides compositions of matter comprising
sets of genes, expressed sequence tags (ESTs), polynucle
otides and polypeptides encoded by said polynucleotides

FIG. 1 is a set of bar graphs shoWing age-dependent impair
ment of memory performance. Male Fischer 344 rats aged 4
50

signi?cantly reduced performance on 24 hr memory retention
on both the Morris spatial Water maZe task (SWM; FIG. 1A)

identi?ed as being involved in the aging processes. These sets

usefully result in a statistically validated, comprehensive
overvieW of mammalian, including human, functional brain
aging. In particular, the set of genes can be used for the
diagnosis of human age-related disease, such as an age-re

months (Young, n:l0), 13 months (Mid-Aged, n:l0) and 24
months (Aged, n:l0) Were used. Aged animals exhibited
and object memory task (OMT; FIG. 1B) in comparison to
either Young or Mid-Aged animals (*p<0.05, **p<0.0l, by

lated neurodegenerative condition, including AlZheimer’s

l-Way ANOVA and Tukey’s post-hoc). As shoWn in the bar
graph, the Young and Mid-Aged animals did not differ sig

disease or Parkinson disease.

ni?cantly from each on either the SWM or OMT task. On the

55

SWM task (FIG. 1A), higher platform crossings re?ects

The invention provides a set of biomarkers for brain aging,
Where (a) the set of biomarkers comprises at least tWo mem

conventional statistical method (such as ANOVA or student’ s

greater retention of the spot Where the platform Was previ
ously located. For the OMT (FIG. 1B), a higher memory
index re?ects greater retention of the previously explored
object, and resultant increased exploration of the novel

t test), With p<0.05; (c) the brain expression patterns of the

object.

bers; (b) the brain expression patterns of the members of the

60

set are signi?cantly altered With aging as determined by a

FIG. 2 is a ?oW chart for a ?ltering and statistical test

members of the set are correlated (using a conventional sta

tistical correlation test, e.g., tested by Pearson’s or Spear
man’s correlation test) across age groups With cognitive per
formance in behavioral tests, With a correlation of p<0.05 (or

65

algorithm for identifying primary set ofACGs. The ?oW chart
also includes the results for an example of the invention. An
initial set of 8,799 transcript sets contained on the U34A Gene

US 7,739,056 B2
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Chip (see, EXAMPLE 2) Was ?ltered prior to statistical test
ing, to reduce expected false positives. Probe sets Were
removed if they Were called “absent” (1a.), if they Were
unknown expressed sequence tags (ESTs) (1b.) or if the dif
ference betWeen theYoung andAged groups did not comprise
at least 75% of the maximal normalized age differences (10.).
Each of the remaining 1,985 transcript (gene) sets Was then

regulation of neuronal (N) oxidative pho sphorylation trigger
ing a cascade of impaired IEG signalling, biosynthetic poten
tial, and critically, decreased capacity for neurite remodeling
and synaptogenesis. In parallel, enhanced lipid metabolism
and demyelination are triggered in oligodendrocytes (O) by
altered energy metabolism or neural activity. In turn, astro

cytes (A) hypertrophy and increase glycolysis of the glucose
taken up by astrocytic endfeet on capillaries (C). Simulta

tested by ANOVA across the three age groups (n:9—10) to

neously, phagocytosis of myelin fragments triggers oxidative

determine if it changed signi?cantly With aging (2.). Each of
the 233 genes that changed signi?cantly With age (p§0.025)

damage and in?ammatory responses in microglia (M). Even
tually, the combined effects of reduced synaptic remodeling,

Was then tested across all animals (n:29) for signi?cant
behavioral correlation With OMT, SWM, or both SWM and

decreased activity and axon conduction, altered extracellular
matrix and expanding in?ammation result in cognitive failure
and neuronal vulnerability.

OMT (Pearson’s; 3a). Furthermore, of the genes that did not
correlate With behavior, ones that shoWed an ANOVA p

value§0.001 Were also retained for further analysis (3b). In
total, 172 genes Were considered, 161 of Which could be
considered ACGs.
FIG. 3 is a set of line graphs shoWing correlation of gene
expression and OMT across individual animals. Behavioral

DETAILED DESCRIPTION OF THE INVENTION

The concept of “biomarker” is Well-knoWn and useful con
cept for those of skill in the genomic art. In general, a biom
20

correlation is measured across all age groups. For genes that

decreased With aging, the ?ve best positive correlations (A)
and for genes that increased With aging, the ?ve best negative
correlations (B) are shoWn (see Legend: correlation p-values
in parentheses). Standardized values for both expression and

of biomarkers for brain aging, using gene expression microar
25

OMT performance are shoWn on theY-axis. The animals Were

change With brain aging alone, based on formal statistical

testing.
30

among the ?ve most highly correlated genes that decreased
With aging, Whereas those related to actin assembly and

short-term memory, long-term memory and memory
retrieval, among others.
35

tional categories and age course of genes decreased With

highly similar to the ones already depicted). Each gene’s
expression Was normaliZed prior to calculating category

“Mid-aged” is de?ned in tWo Ways: at or around half the

average lifespan for the species and at or around the midpoint
40

the group to Which they are most closely chronologically

exhibited 250% of mean changes by the Mid-Aged point,
and shoWed relatively less change betWeen the Mid-Aged and
Aged animals. No category shoWed a predominantly Mid-to
Aged pattern of change. The pie-chart insert shoWs propor

related (With the exception of young animals, for Whom it
Would be inappropriate to include prepubescent individuals)
We used the bioinformatics and functional correlation

strategy of the invention for microarray analyses. As a result,

tion of genes that folloWed each of the three possible routes to

We Were able to detect multiple groups of related genes that

decreased expression With aging.

Were altered by brain aging and also correlated With cognitive
50

tional categories and age course of genes increased With

function is not altered substantially Without further progres
sion and/or the cumulative effects of the initial changes in
55

60

terns Were seen When all upregulated genes are considered

(Pie-chart inset).
FIG. 6 is a micrograph shoWing a model of parallel neu

ronal and glial cascades leading to functional impairment.
Early in mid-life, initiating factors (e.g., reduced neuronal
activity, onset of late-acting gene expression) induce doWn

gene regulation.
This analysis depended on a novel combination of three

Calculations and nomenclature as in FIG. 4. Note that, in

contrast to the majority of doWnregulated genes (FIG. 4),
changes in upregulated categories did not tend to level off
after mid-life but instead shoWed continuing change betWeen
mid-life and late-life (e.g., a monotonic pattern). Similar pat

function across individual subjects. Most of the shifts in

genomic regulation began by mid-life, Well before the onset
of measurable cognitive impairment, implying that cognitive

aging. Chronological patterns are shoWn for aging changes
for ?ve of the eleven functional categories of behaviorally
correlated upregulated genes (some categories Were omitted
to increase legibility and because their pattern of change With
age Was highly similar to that of categories already depicted).

betWeen reproductive maturity and average lifespan. “Aged”
mammals are those at or around average lifespan. Animals
intermediate betWeen tWo ages could be considered as part of

mean values. Note that most doWn-regulated categories

FIG. 5 is a line graph and pie chart insert shoWing func

As used in this speci?cation, across different mammalian
species, age de?nitions are as folloWs: “Young” mammals are

those at or beyond reproductive maturity for the species.

aging. Chronological patterns are shoWn for aging changes
for ?ve of the eight functional categories (some categories
Were omitted to improve legibility and because they Were

As used in this speci?cation, the Word “cognitive” is
de?ned as comprising the higher order intellectual/brain pro

cesses involved in learning, including attention, acquisition,

in?ammation Were among the ?ve most highly correlated

genes that increased With aging.
FIG. 4 is a line graph and pie chart insert shoWing func

rays and behavioral testing. The method of the invention
alloWs one skilled in the genomics art to identify both “aging

and cognition-related genes” (ACGs) and unique genes that

ranked for OMT performance on the X-axis, from Worst (1) to
best (29), and OMT performance Was plotted as a heavy black
line on both A and B for the purposes of comparison. Genes

involved in early responses and synaptic remodeling Were

arker is a measurable biological manifestation that is a quan

titative indication of the presence and degree of an underlying
biological process of interest.
We have devised a multi-stage method for the identi?cation

65

approaches for microarray research: (a) the quantitative mea
surement of the dependent function of interest (cognitive
performance), Which provided a basis for large-scale expres
sion-function correlation analyses; (b) the application of for
mal statistical analyses (ANOVA, Pearson’s) to large groups
of independent microarray samples, Which conferred sub
stantial statistical poWer and high detection sensitivity for
even modest changes (loW false negative type II error); and c)
systematic estimates of the maximum probabilities of false
positives in our data. Our results using the method of the

invention provide a generally comprehensive overvieW of

US 7,739,056 B2
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hippocampal genes/processes that are altered With brain
aging and closely linked to brain functional decline.
To verify the method of the invention, We ?rst tested young

performed the same analyses and compiled the same lists for
unidenti?ed expressed sequence tags (ESTs) that are on the

(3-4 months old), mid-aged (12-13 months old) and aged
(24-25 months old) rats (n:9-10 per group) for performance

because once the ESTs are identi?ed, they can provide thera

In addition to these lists for identi?ed genes, We have also

same Affymetrix Chips (TABLE 2). These are valuable data,

on the Morris spatial Water maZe (SWM) and object memory

peutic targets.

task (OMT). Both behavioral tests clearly and reliably (sta

Using the method of the invention, We Were able to identify
a number of processes and pathWays that previously have not
been clearly associated With normal brain aging. The most

tistically) revealed aging-related cognitive impairment (FIG.
1).

unexpected ?ndings included altered expression pro?les sug

We then anesthetiZed (for euthanasia) all animals and dis
sected out a region of the brain (CA1 region of the hippoc
ampus) knoWn to be important for memory. These brain tis
sues Were then prepared for analyses of gene expression

gestive of increased myelin and lipid turnover, as Well as

Widespread changes indicating coordinated doWnregulation
of oxidative metabolism, decreased neurite outgroWth and
synaptogenesis. Other novel genes We identi?ed appear to

pro?les (mRNA content) on Affymetrix GeneChip microar

suggest alterations in general metabolic and biosynthetic
chaperone functions. In addition, many of the identi?ed

rays speci?c for the rat genome (RG-U34A arrays) (one array
for each individual rat sample). The microarrays Were then
read and analyZed for expression pro?le data on an Affyme
trix GeneChip System according to the manufacturer’s
instructions.
The behavioral and microarray methods that Were used can
reasonably be expected to apply as Well to mice as to rats.
Similar behavioral and microarray methods knoWn to those of
skill in the art can be used for testing of other mammals,

20

extent of the changes and the concurrent upregulation of

potentially orchestrating transcription factors and cytokines
25

potential interactions among the multiple altered expression
30

of the effects of aging. Using Analysis of Variance (ANOVA)
We de?ned the set of genes Whose degree of expression
changed signi?cantly With brain aging. We then used that set

of “Aging Genes” and tested each gene’s expression pro?le
(across only the aged animals) for signi?cant correlation With

that may provide important clues to pathogenic mechanisms.
In order to begin to develop an integrative overvieW of

including humans. The utility of the method of the invention
for human testing is discussed beloW.
We then transferred the data into standard computer

spreadsheets (e.g., Excel) for performing statistical analyses

groups con?rmed previously described changes in expression
for genes regulating several major processes (e.g., in?amma
tion, glial reactivity, oxidative stress). HoWever, our results
also extend the earlier ?ndings considerably by revealing the

patterns observed here, We considered functional implica
tions at the pathWay level. Our interpretations rely on the
functions that have been previously associated With many of
the genes identi?ed by those of skill in the genomics art.
These are identi?ed through PubMed literature searches,

annotations provided by Affymetrix, entries in the SWissPro
tein database and associations reported in the Genome Ontol
35

ogy (GO). We also rely on the general assumption held by

memory performance on the Object Memory Task (OMT) as
Well as the Morris spatial Water maZe (SWM). The “Aging

those of skill in the genomics art that similar changes in the

Genes” Whose expression patterns correlated signi?cantly

like changes in the functions mediated by the encoded pro
teins of that pathWay. Gene expression changes also can

expression of multiple genes of a particular pathWay imply

With cognitive performance Were de?ned as the primary sub

set of “Aging and Cognition-Related Genes” (ACGs), and

40

re?ect compensatory negative feedback regulation (or other
dissociations of gene expression and protein function), but

subcategoriZed as OMT-associated, SWM-associated, or
both OMT and SWM-associated. We further included genes

the potential confound of dissociation is presumably less of a

With no behavioral association that had an ANOVA p

problem in microarray analyses in Which multiple genes in a

value§0.001 since genes identi?ed at this more stringent

level are less subject to the error of multiple testing (FIG. 2,
TABLES 1A and 1B).

45

of the primary metabolic pathWays and processes considered
in the interpretations are depicted in TABLE 1.

Based on those large-scale studies, We have developed a list

of ACGs that appear to have considerable potential impor
tance for assessing and generating neW treatments for age

Functional Groups. We found age-dependent upregulation
50

dependent functional decline (TABLES 1A and 1B).

55

viously shoWn to be speci?cally associated With both brain

aging and aging-dependent cognitive impairment. Further,
many genes on our list have not even been shoWn previously

to be linked to brain aging alone or to cognition alone. Thus,
our lists ofACGs are unique and useful biomarkers and thera

60

peutic targets speci?cally for aging-dependent cognitive

unique panel of gene biomarkers and therapeutic targets for
study and treatment of brain aging.

recogniZed to change With normal aging. These included
upregulation of genes for myelin proteins, cholesterol bio
synthesis and transport, amino acid metabolism, intracellular
Ca2+ signaling, and protein processing, as strongly suggest
ing an ongoing cycle of remyelination and demyelination. We
also found Widespread doWnregulation of genes for biosyn
thesis, immediate early responses, and synaptic structural
plasticity, suggestive of neuronal involution. Multiple tran
scriptional regulators and cytokines Were also identi?ed that

may play orchestrating roles. Nearly all expression changes

impairment. In addition, our list of all genes that change With
brain aging contains many genes never before reported to

change With brain aging, and therefore provides a useful and

of many ACGs involved in in?ammatory/immune/ stress
responses and doWnregulation of many involved in energy
metabolism. In addition, We found alterations of gene expres

sion re?ecting multiple categories/pathways not previously

These lists contain some genes that Were identi?ed previ

ously as being linked to brain aging or neurodegeneration
(e.g., in?ammation or mitochondrial genes, Lee C K et al.,
Nature Genetics 25: 294-297 (2000)) but none has been pre

pathWay are observed to change in the same direction. Some

65

began by mid-life but cognition Was not impaired until late
life. Upregulated genes for in?ammation and intracellular
Ca2+ release Were among those most closely correlated With

impairment.
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TABLE 1A
Functionally Grouped ACGs and Genes Showing
Highly Signi?cant Age-Dependent Decreases in Expression
SEQ ID NO:

GenBank

Description

Young

Mid

Aged

ANOVA p beh all

2746 r 105
10324 1 546

2334 r 74
8990 r 327

2207 r 79
8165 r 480

0.0005
0.0095

Both
Both

4358 r 300

3470 r 143

3247 r 185

0.0029

OMT

6697 r 373
10339 1 180

5836 r 387
9322 r 258

4722 r 369
9388 r 330

0.0042
0.0239

OMT
OMT

3546 r 270
6374 r 527

2354 r 121
4408 r 228

2469 r 132
4094 r 398

0.0001
0.0008

None
None

4911 r 259

3688 r 177

3544 r 165

0.0001

Both

2037 r 149

1576 r 44

1495 r 170

0.0009

Both

1467 r 80

1186 r 83

1011 r 62

0.0010

Both

471 r 31

397 r 31

314 r 22

0.0022

Both

1900 r 129
2480 r 67
7645 r 169

1503 r 95
2396 r 41
7690 r 183

1365 r 103
2097 r 73
6842 r 250

0.0059
0.0004
0.0106

Both
OMT
OMT

576 r 95
1166 r 15

223 r 21
928 z 55

205 r 23
887 z 38

0.0001
0.0001

SWM
SWM

3607 r 142
526 r 40

2993 r 91
275 r 49

3025 r 66
272 r 46

0.0003
0.0007

None
None

1781 r 92

1528 r 88

0.0030

Both

Synaptic Structural Plasticity
SEQ ID NO: 1
SEQ ID NO: 2

M64780*
L21192

Agrn, Agrin
GAP-43, membrane attached signal

SEQ ID NO: 3

S82649

Narp, neuronal activity-regulated

protein 2 (brain)

pentraxin
SEQ ID NO: 4
SEQ ID NO: 5

M74223
U63740*

SEQ ID NO: 6
SEQ ID NO: 7

AB003726
U19866

VGF, neurosecretory protein
Fez1, Protein kinase C-binding

protein Zeta1
Homerla, RuvB-like protein 1
Arc, activity-regulated cytoskeleton-

associated protein

Transcription Regulator
SEQ ID NO: 8

M18416

Egr1, Early groWth response 1 (Krox-

24)
SEQ ID NO: 9

M92433

SEQ ID NO: 10

L08595

NGFI-C, Zinc-?nger transcription
factor
Nuclear receptor subfamily 4, group

A, member 2
SEQ ID NO: 11

AI030089

Nopp130, nucleolar phosphoprotein

p130
SEQ ID NO: 12
SEQ ID NO: 13
SEQ ID NO: 14

AF016387
AA800794
AA799641

RXRG, retinoid X-receptor gamma
HT2A, Zinc-?nger protein
S164, Contains a PWI domain

SEQ ID NO: 15
SEQ ID NO: 16

U78102
U44948

Egr2, Early groWth response 2
SmLIM, smooth muscle cell LIM

SEQ ID NO: 17
SEQ ID NO: 18

AA891717
AF095576

USP-1, upstream stimulatory factor 1
Aps, adaptor protein With pleckstrin
and src homology

associated With RNA splicing

protein

Intracellular Signal Transduction
SEQ ID NO: 19

AI176689

SEQ ID NO: 20

X89703

SEQ ID NO: 21

L04485

SEQ ID NO: 22

AA817892

MAPKK 6, mitogen-activated protein
kinase kinase 6
TPCR19, Testis Polymerase Chain

2012 r 84
361 r 25

320 r 25

252 r 24

0.0155

Both

13110 1 365

11951 1 312

11200 1 506

0.0104

OMT

6500 r 159

5606 r 214

5765 r 218

0.0110

OMT

597 z 43
1994 r 110

444 z 51
1723 r 90

391 z 47
1544 r 114

0.0150
0.0202

OMT
OMT

9443 r 360
637 r 72

9064 r 478
674 r 61

7857 r 323
455 r 35

0.0228
0.0228

OMT
OMT

782
1078
367
605
3561

630
1068
332
568
3668

23
74
27
57
141

0.0119
0.0093
0.0233
0.0247
0.0004

Both
OMT
SWM
SWM
None

23
15
19
9
17

0.0005
0.0024
0.0180
0.0120
0.0128

Both
Both
Both
SWM
SWM

37
54
97
128
322

0.0000
0.0002
0.0010
0.0013
0.0061

Both
Both
Both
Both
Both

Reaction product 19
MAPPK1,mitogen-activated protein
kinase kinase 1
Gnb2, Guanine nucleotide binding

protein (beta 2subunit)
SEQ ID NO: 23
SEQ ID NO: 24

AF000901
M87854

SEQ ID NO: 25
SEQ ID NO: 26

AF058795
AA800517

P58/P45, Nucleoporin p58
Beta-ARK-l, beta adrenergic

receptor kinase 1
Gb2, GABA-B receptor
VAP1, vesicle associated protein

Signal Transduction
SEQ
SEQ
SEQ
SEQ
SEQ

ID NO:
ID NO:
ID NO:
ID NO:
ID NO:

27
28
29
30
31

AF003904
M15191
AF091563
M64376
M15880

CRH-binding protein
Tac1, Tachykinin
Olfactory receptor
Olfactory protein
Npy, NeuropeptideY

773
1415
440
810
4647

z 51
:110
z 21
z 26
r 158

z
r
z
z
r

35
57
29
83
223

z
r
z
z
r

Adhesion, Extracellular Matrix
SEQ
SEQ
SEQ
SEQ

ID NO:
ID NO:
ID NO:
ID NO:

32
33
34
35
SEQ ID NO: 36

M27207
AF104362
D63886
M21354
AB010437

Colla1, Procollagen-type I (alpha 1)
Omd, Osteomodulin (osteoadherin)
MMP16, matrix metalloproteinase 16
Col3a1, collagen type III alpha-1

678
289
664
203
163

CDH8, Cadherin-8

r
r
r
z

24
16
23
22

z 24

521
217
604
157

r 43
r 24
r 37
z 13
100 z 12

480
185
542
132

r
r
r
z
83 z

Metabolism
SEQ
SEQ
SEQ
SEQ
SEQ

ID NO:
ID NO:
ID NO:
ID NO:
ID NO:

37
38
39
40
41

SEQ ID NO: 42

L03294
S68245
AA859975
M24542
M18467
X64401

Lp1, lipoprotein lipase
Ca4, carbonic anhydrase 4
LOC64201, 2-oxoglutarate carrier
RISP, Rieske iron-sulfur protein
Got2, glutamate oxaloacetate
transaminase 2
Cyp3a3, Cytochrome P450-subfamily

1147
2272
4792
10337
9470

r
r
r
1
r

69
75
68
308
241

918
1993
4370
9095
8355

r 40
r 63
r 102
r 327
r 179

749
1825
4255
8833
8332

r
r
r
r
r

805 r 64

762 r 51

581 r 34

0.0089

Both

2054 r 73

1988 r 77

1673 r 111

0.0127

Both

III (polypeptide 3)
SEQ ID NO: 43

U83880

glycerol-3-phosphate dehydrogenase,

mitochondrial
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TABLE lA-continued
Functionally Grouped ACGs and Genes Showing
Highly Signi?cant Age-Dependent Decreases in Expression
SEQ ID NO:

GenBank

Description

SEQ ID NO: 44
SEQ ID NO: 45
SEQ ID NO: 46

105499
U90887
M22756

GLS, glutaminase (mitochondrial)
Arg2, arginase type II
Ndu?/2, mitochondrial NADH

Young

Mid

Aged

ANOVA p beh all

915 r 24
499 z 21
12293 1 574

844 r 44
374 z 31
10193 1 670

787 r 14
364 z 22
9260 r 750

0.0238
0.0015
0.0134

Both
OMT
SWM

426 r 30
802 z 20
687 r 33

411 r 24
659 z 40
521 r 22

292 r 27
691 z 37
480 r 38

0.0028
0.0198
0.0002

Both
OMT
SWM

353 z 21

324 z 25

251 z 23

0.0150

SWM

3159 r 81

2747 r 74

2637 r 97

0.0006

Both

820 z 31
5335 r 73

676 z 31
4906 r 186

662 z 38
4600 r 162

0.0051
0.0090

Both
Both

r 29
1 457
r 135
r 141

0.0109
0.0047
0.0104
0.0149

Both
OMT
OMT
OMT

dehydrogenase (24 kDa)
Transporters, Carriers
SEQ ID NO: 47
SEQ ID NO: 48
SEQ ID NO: 49

L46873
AB000280
U87627

SEQ ID NO: 50

AA799389

Slc15a1, Oligopeptide transporter
PHT1, peptide/histidine transporter
MCT3, putative monocarboxylate

transporter
Rab3B, ras-related protein

Growth, Biosynthesis, Maintenance
SEQ ID NO: 51

X16554

Prps1, Phosphoribosyl pyrophosphate

synthetase 1
SEQ ID NO: 52
SEQ ID NO: 53

U66470
M37584

SEQ
SEQ
SEQ
SEQ

U90610
AA874794
AA892506
AA893939*

rCGR11, Cell growth regulator
H2AZ, H2A histone family (member

Z)
ID NO:
ID NO:
ID NO:
ID NO:

54
55
56
57

Cxcr4, CXC chemokine receptor
Bex3, brain expressed X-linked 3
coronin, actin binding protein 1A
DSS1, deleted in split hand/split foot

811
16735
4101
4201

r
1
r
r

56
376
121
76

812
14986
3625
3860

r
1
r
r

59
588
114
129

614
14238
3558
3658

protein 1
SEQ ID NO: 58
SEQ ID NO: 59
SEQ ID NO: 60

AF087037
U06099
AI172476

Btg3, B-cell translocation gene 3
Prdx2, Peroxiredoxin 2
Tieg-1, TGF-beta-inducible early

SEQ ID NO: 61

AA866411

Necdin, neuronal growth suppressor

652 r 55
12667 1 675
1127 r 99

676 r 71
11742 1 641
925 z 63

460 r 29
10339 1 272
812 z 53

0.0163
0.0216
0.0177

OMT
OMT
SWM

1994 r 81

1568 r 86

1542 r 62

0.0005

None

10088 1 333
997 r 161

9602 r 299
728 r 99

8693 r 229
470 r 59

0.0071
0.0095

Both
Both

7298 r 242

6892 r 229

6395 r 177

0.0241

Both

10716 1 382
3131 r 292

8836 r 190
2040 r 196

8392 r 204
2006 r 135

0.0000
0.0012

SWM
None

growth response protein 1

Protein Processing and Traf?cking
SEQ ID NO: 62
SEQ ID NO: 63

X54793
AA875047

SEQ ID NO: 64

D21799

Hsp60, heat shock protein 60
TCPZ, T-complex protein 1 (Zeta

subunit)
Psmb2, Proteasome subunit (beta type

2)
SEQ ID NO: 65
SEQ ID NO: 66

U53922
X78605

Hsj2, DnaJ-like protein (RDJ1)
rab4b, ras-homologous (GTPase

For TABLE 1A, “GenBank” is the gene accession number
established at the web accessible GenBank database, The
“Description” includes a ‘common name’ (if applicable) as
well as a brief description of the gene product. Values for

40

and behavioral correlation was that comprising genes

Young, Mid-Aged, and Aged categories are the meanzSEM
of expression values. Genes are put into functional categories

45

(see, above) and grouped by their level of association with

behavior (expression correlated signi?cantly (Pearson’s;
20.025) with both tasks, with the OMT, with the SWM, or
with none of the tasks but highly signi?cant across age
(20.001 on ANOVA across age, p>0.025 for correlation on

50

both SWM and OMT). Within each level of association,
genes are ranked by the signi?cance of the age-dependent

change in their expression level (ANOVA; 20.025). Aster
isked (*) genes are those that also showed a signi?cant behav

ioral correlation (Pearson; 20.025).
ACGs that were downregulated with aging (TABLE 1A)

55

appeared primarily to represent metabolic and neuronal func

mitochondrial electron transport chain (e.g., glycerol 3 -phos
phate dehdrogenase, NADH dehydrogenase, Rieske’s iron
sulpher protein) were downregulated with aging (TABLE
1A). Moreover, we found aging-dependent downregulation
of several genes related to pathways important for glucogenic
amino acid catabolism, including glutaminase and arginase

(TABLE 1A).

involved in synaptic structural plasticity, including neurite
outgrowth and synaptogenesis (e.g., decreased expression of
genes encoding agrin, GAP-43, Homer 1a, Narp, Arc, etc.)
(TABLE 1A). Many of these genes are activity-dependent in
neurons and have been linked previously to synaptic plastic
ity, neurite remodeling or learning in univariate studies (e.g.,
Biewenga J E et al., Acia Biochim Pol 43: 327-38 (1996);
Steward O et al., Neuron 21: 741-51 (1998), Mantych K B &
Ferreira A, J Neurosci 21 : 6802-9 (2001 ), GuZowski J F et al.,
J Neurosci 20: 3993-4001 (2000), BeZakova G, et al. Proc
Natl Acad Sci USA 98 9924-9 (2001)), although Gap-43 is
one of the few reported so far to change with aging. Similarly,
many other neural activity-dependent genes, including IEGs

in the Transcription Regulators and Signaling categories
(e.g., Egrl, Egr2, MAPKK, etc.), showed decreased expres
sion with aging and were correlated with impaired cognition

tions (FIG. 3a).
Metabolism. Multiple genes related to functions of the

Synaptic Structural Plasticity. One of the most prominent
categories of identi?ed genes showing decreased expression

(TABLE 1A).
60

In addition, multiple genes important for general growth

65

and biosynthetic mechanisms, chaperone functions and pro
tein processing were also downregulated with aging (e.g.,
hsp60, histone H2AZ, proteasome subunit, DNA J-like
homolog, etc.) as were speci?c neuronal signaling genes
(e.g., GluR 5-2, the kainate receptor; and neuropeptide Y)

(TABLE 1A). These widely downregulated biosynthetic and
signaling genes appear to re?ect a general involution of meta

US 7,739,056 B2
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bolic and neurite structural remodeling processes in neurons

(e.g., FIG. 4, TABLE 1A). Chaperone proteins such as the
DNA-J-like homolog and hsp60 play critical roles in preyent
ing protein aggregates (Satyal S H et al., Proc Natl Acad Sci

Neurosci 21: 479-505 (1998), Koyacs D M &TanZi R E, Cell
M0! Life Sci 54: 902-9 (1998); Sisodia S S et al., Am JHum
Genet 65: 7-12 (1999), TanZi R E & Parson A B (2000),
Selkoe D J, Neuron 32: 177-80 (2001)), and could therefore

USA 97 5750-5 (2000)), Which are knoWn to be critical in

have implications for age-dependent Vulnerability to AlZhe

AlZheimer’s disease (Price D L & Sisodia S S, Annu Rev

imer’s disease.

TABLE 1B
ACGs and Genes Showing Highly Signi?cant Age-Dependent Increases in Expression
SEQ ID NO:

GenBank

Description

Young

Mid

Aged

ANOVA p beh all

3976 r 248
885 r 52

6891 r 350
1461 r 85

8365 r 438
1895 r 102

0.0000
0.0000

Both
Both

368 r 43

695 r 60

910 r 45

0.0000

Both

0.0000
0.0000
0.0000
0.0000
0.0000

Both
Both
Both
Both
Both

In?ammation, Defense, Immunity
SEQ ID NO: 69
SEQ ID NO: 70

104488
X71127

Ptgds, Prostaglandin D synthase
Clqb, complement component l-q

SEQ ID NO: 71

103752

Microsomal GST-l, glutathione S-

(beta polypeptide)
SEQ
SEQ
SEQ
SEQ
SEQ

ID
ID
ID
ID
ID

NO:
NO:
NO:
NO:
NO:

transferase
MHC class I RT1.C-type protein
Aifl, allograft in?ammatory factor 1

72
73
74
75
76

L40362*
U17919
M15562
X13044
M24324

SEQ ID NO: 77

M32062

Fcgr3, Fc IgG receptor III (10W af?nity)

347 r 25

462 r 32

557 r 21

0.0000

Both

SEQ ID NO: 78
SEQ ID NO: 79

AJ222813
L40364

I118, interleukin 18
RT1AW2, RT1 class Ib

110 z 33
2033 r 126

208 z 14
2546 r 127

261 z 16
2842 r 115

0.0002
0.0004

SEQ
SEQ
SEQ
SEQ

AI231213
AI170268
X52477
X73371

Kangai 1, suppression oftumorigenicity 6
Ptgfr, Prostaglandin F receptor
C3, Complement component 3
FCGRZ, LoW af?nity immunoglobulin
gamma Fc receptor II
Gstal, Glutathione-S-transferase (alpha

2727
6651
34
218

2952
8057
236
285

3484
8502
476
384

139
359
100
21

0.0008
0.0013
0.0034
0.0001

Both
Both
Both
Both
Both
OMT

0.0009

OMT

MHC class II RT1.u-D-alpha chain
Cd74, CD74 antigen
RTS, MHC class I RT1 (RTS(u

1755
712
608
—49
3274

r 64
r 29
z 73
z 44
r 175

2106
990
1194
155
4599

r 82
r 47
r 238
z 83
r 363

2501
1152
2120
603
5822

r
r
r
z
r

77
67
173
100
342

haplotype)

ID
ID
ID
ID

NO:
NO:
NO:
NO:

80
81
82
83

SEQ ID NO: 84

X78848

r 116
r 248
r 49
z 19

r
r
r
z

120
336
83
24

r
r
r
z

3145 r 74

3909 r 188

4155 r 204

typ?)
SEQ ID NO: 85

AA818025*

Cd59, CD59 antigen

6465 2 265

7269 2 163

7474 2 189

0.0052

OMT

SEQ ID NO: 86
SEQ ID NO: 87
SEQ ID NO: 88

AA891810
U92081
X62322

GST, Glutathione S-transferase
Gp38, Glycoprotein 38
Grn, Granulin

1136 r 83
547 z 26
4514 r 145

1411 r 70
679 z 38
4972 r 254

1791 r 101
802 z 66
5375 r 119

0.0001
0.0037
0.0116

SWM
SWM
SWM

112 z 30
472 r 31

265 z 38
565 r 32

300 z 26
617 r 29

0.0008
0.0099

Both
Both

429 r 50

687 r 71

761 r 50

0.0014

OMT

784 z 100

1054 r 75

1179 r 95

0.0160

OMT

979 z 62
544 z 31

1078 r 68
590 z 36

1338 r 114
687 z 25

0.0193
0.0096

OMT
SWM

Transcription Regulator
SEQ ID NO: 89
SEQ ID NO: 90

X13167*
U67082

NFl-A, nuclear factor 1 A
KZF-l, Kruppel associated box

SEQ ID NO: 91

U92564

RoaZ, Olf-l/EBF associated Zn ?nger

(KRAB) Zinc ?nger 1

protein
SEQ ID NO: 92

L16995

ADD1, adipocyte detenn/different-

dependent factor 1
SEQ ID NO: 93
SEQ ID NO: 94

AI237535
AI177161

LitaF, LPS-induced TNF-alpha factor
Nfe212, NF-EZ-related factor 2

Signal Transduction
SEQ ID NO: 95

U26356

S100A1, S100 protein (alpha chain)

1382 r 105

1636 r 75

1999 r 115

0.0008

Both

SEQ ID NO: 96
SEQ ID NO: 97
SEQ ID NO: 98

AA850219
D84477
AF048828

Anx3,Annexin A3
Rhoa, ras-related homolog A2
VDAC1,voltage-dependent anion

438 z 26
749 r 108
2334 r 294

501 z 21
1069 r 111
3157 r 392

575 z 26
1319 r 85
3844 r 290

0.0023
0.0024
0.0137

Both
Both
Both

SEQ ID NO: 99
SEQ ID NO: 100

AI102103
L35921

channel 1
Pik4cb, Phosphatidylinositol 4-kinase
Ggamma, GTP-binding protein (gamma

975 r 63
498 r 30

1029 r 67
543 r 43

1252 r 80
712 r 64

0.0247
0.0108

Both
SWM

SEQ ID NO: 101

M83561

248 r 23

359 r 22

351 r 12

0.0007

None

3938 r 342
2586 r 110

5112 r 312
2974 r 180

5980 r 242
3460 r 183

0.0003
0.0038

Both
OMT

615 r 45

855 r 61

881 r 59

0.0049

OMT

2889 r 155
13950 1 386

4153 r 196
15483 1 633

4621 r 238
18407 1 909

0.0000
0.0004

Both
Both

5282 r 258

5595 r 140

65 64 r 326

0.0038

Both

2458 r 59
978 r 163

2856 r 148
1544 r 190

3080 r 129
2455 r 332

0.0051
0.0010

OMT
SWM

subunit)
GluR-5, kainite sensitive glutamate

receptor
Adhesion, Extracellular Matrix
SEQ ID NO: 102
SEQ ID NO: 103

E13541
X83231

SEQ ID NO: 104

AF097593

Cspg5, chondroitin sulfate proteoglycan 5
PAIHC3, Pre-alpha-inhibitor, heavy
chain 3
Ca4, cadherin 2-type 1 (neuronal)

Myelin-Related Proteins
SEQ ID NO: 105
SEQ ID NO: 106

M55534
D28111

SEQ ID NO: 107

X06554

SEQ ID NO: 108
SEQ ID NO: 109

S55427
M22357

Cryab, alpha crystalline polypeptide 2
MOBP, myelin-assocated

oligodendrocytic basic protein
S-MAG, myelin-associated glycoprotein
C-term
Pmp, peripheral myelin protein
MAG, myelin-assocated glycoprotein

US 7,739,056 B2
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TABLE lB-continued

ACGs and Genes Showing Highly Signi?cant Age-Dependent Increases in Expression
SEQ ID NO:

GenBank

Description

Young

Mid

Aged

ANOVA p beh all

187 r 35
630 z 54

298 r 30
685 z 91

417 r 38
928 z 67

0.0003
0.0182

Both
Both

368 z 74
5875 r 355
599 r 65

521 z 33
7281 r 601
677 r 59

587 z 35
8343 r 595
854 r 59

0.0128
0.0133
0.0192

OMT
OMT
OMT

Lipid Metabolism/Transport
SEQ ID NO: 110
SEQ ID NO: 111

X54096
S83279

SEQ ID NO: 112
SEQ ID NO: 113
SEQ ID NO: 114

U37138
X55572
L07736

Lcat, Lecithin-cholesterol acyltransferase
HSDIV, 17-beta-hydroxysterold

dehydrogenase type IV
Sts, Steroid sulfatase
Apod, Apolipoprotein D
Cpt1a, Carnitine palmitoyltransferase 1

alpha (liver)
Amino Acid/Transmitter Metabolism
SEQ
SEQ
SEQ
SEQ

ID NO:
ID NO:
ID NO:
ID NO:

115
116
117
118

103481
Z50144
U07971
M77694

DHPR, Dihydropteridine reductase
Kat2, kynurenine aminotransferase II
Transamidinase, mitochondrial
Fah, fumarylacetoacetate hydrolase

13260
106
2897
847

1
r
r
r

369
33
130
36

16897
183
3311
990

1 528
r 19
r 186
r 49

17432
240
3644
1305

1
r
r
r

380
24
182
98

0.0000
0.0040
0.0183
0.0002

Both
Both
OMT
SWM

998
117
5004
270
488

z 162
z 90
r 333
r 81
r 49

1346
357
5651
232
626

r
z
r
r
r

122
79
278
82
72

0.0016
0.0080
0.0120
0.0236
0.0249

Both
Both
Both
OMT
OMT

Cytoskeletal, Vesicle Fusion
SEQ
SEQ
SEQ
SEQ
SEQ

ID
ID
ID
ID
ID

NO:
NO:
NO:
NO:
NO:

119
120
121
122
123

SEQ ID NO: 124

X62952
AA892333
U11760*
U32498*
AF083269*

Vim, vimentin
Tubal, alpha-tubulin
Vcp, valosin-containing protein
RSEC8, rat homolog ofyeast sec8
P41-Arc, actin-related protein complex

AF028784

1b
GFAP, glial ?brillary acidic protein

571
—52
4314
—11
406

z
z
r
r
r

100
83
234
37
23

19860 1 714

19731 1 1002

23241 1 1058

0.0217

SWM

8698
5416
16431
17259
153

13715
7407
19831
23893
152

1 1017
r 511
1 1519

0.0000
0.0000
0.0001

Both
Both
Both

1 1426

0.0000

OMT

r 13

0.0018

SWM

0.0000

Both

Transporters, Carriers
SEQ
SEQ
SEQ
SEQ
SEQ

ID
ID
ID
ID
ID

NO:
NO:
NO:
NO:
NO:

125
126
127
128
129

M94918
U31866
D38380

Hbb, beta hemoglobin
Nclone10
Tf, Transferrin

X56325

Hba1, alpha 1 homoglobin

AF008439

Natural resistance-associated

6172
3625
11990
14433
69

r 737
r 302
1 728

1 611
r 17

r 646
r 561
1 707

1 959
r 19

macrophage protein 2
GroWth, Biosynthesis, Maintenance
SEQ ID NO: 130

AA799645

FXYD domain-containing ion

1680 r 58

2025 r 68

2457 r 129

transport regulator 1
SEQ
SEQ
SEQ
SEQ
SEQ
SEQ

ID NO:
ID NO:
ID NO:
ID NO:
ID NO:
ID NO:

131
132
133
134
135
136

L03201
M27905
AA893493
X52619
X14181*
M31076

Ctss, cathepsin S
Rpl21, Ribosomal protein L21
RPL26, Ribosomal protein L26
Rpl28, Ribosomal protein L28
RPL18A, Ribosomal protein L18a
TNF-alpha, Transforming groWth

SEQ
SEQ
SEQ
SEQ
SEQ

ID NO:
ID NO:
ID NO:
ID NO:
ID NO:

137
138
139
140
141

AI171462*
X68283
X53504*
U77829
AI234146

Cd24, CD24 antigen
Rpl29, Ribosomal protein L29
RPL12, Ribosomal protein L12
Gas-5, groWth arrest homolog
Csrpl, Cysteine rich protein 1

17087
11279
18442
13167
8623
139

1 393
1 905
1 688
1 323
r 430
r 23

19066
13999
23043
13231
10171
241

1 691
1 389
1 506
1 310
1 389
r 43

22376
15557
24252
14520
11025
295

1
1
1
1
1
r

875
379
1162
228
602
35

0.0001
0.0001
0.0001
0.0034
0.0068
0.0167

Both
Both
Both
Both
Both
Both

z
r
r
r
r

1270
9500
11398
228
4925

r
r
1
r
r

1304
10807
11719
264
5451

r
1
1
r
r

101
267
620
20
179

0.0026
0.0050
0.0241
0.0030
0.0243

OMT
OMT
OMT
SWM
SWM

factor (alpha)
864
9705
9877
173
4436

69
262
328
15
335

86
300
367
14
207

Protein Processing and Traf?cking
SEQ ID NO: 142

M32016

Lamp2, lysosomal-associated

759 r 38

906 r 36

1092 r 74

0.0008

Both

16577 1 368
1077 r 38

17202 1 429
1163 r 69

18363 1 368
1317 r 49

0.0116
0.0158

OMT
OMT

208
109
56
37

0.0215
0.0247
0.0010
0.0043

OMT
OMT
SWM
SWM

1461 1122
344 r 51

0.0097
0.0015

SWM
None

membrane protein 2
SEQ ID NO: 143
SEQ ID NO: 144

B01534
AI028975

Rps15, Ribosomal protein S15
AP-I, adaptor protein complex (beta

SEQ
SEQ
SEQ
SEQ

AI175486
AF023621
AI230712
AA891445*

Rps7, Ribosomal protein S7
Sort1, sortilin
Pace4, Subtilisin ilike endoprotease
Skd3, suppressor of K’“ transport
defect 3
Stx7, Syntaxin 7
Pdi2, peptidyl arginine deiminase

1)
ID NO:
ID NO:
ID NO:
ID NO:

145
146
147
148

SEQ ID NO: 149
SEQ ID NO: 150

AF031430
AA900516

5820
414
281
321

r
z
r
r

448
34
31
24

794 :133
57 r 42

6409
813
447
440

r
z
r
r

312
143
49
42

1387 r 188
314 r 62

7212
812
570
508

r
z
r
r

(WPe 11)
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main unexpected ?ndings Was a Widespread upregulation in

The analyses for TABLE 1B are as described for TABLE
1A.

Upregulated Genes. Genes that Were upregulated With

aging and negatively correlated With behavior ?t primarily
into categories that appeared to re?ect activated glial func
tions (FIGS. 3B and 5, TABLE 1B). Additionally, among the

65

the expression of genes encoding proteins for myelin synthe
sis and lipid turnover (TABLE 1B).
Lipid Metabolism. Multiple genes important for mitochon
drial and cytosolic lipid [3-oxidation (e.g., carnitine palmi
toyltransferase, lecithin-cholesterol acyltransferase, etc.;

US 7,739,056 B2
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TABLE 1B), the primary pathway for free fatty acid (FFA)

Consistent With evidence of a role for oxidative stress in

Increased Myelin Synthesis, Cholesterol Biogenesis and
Vesicle Transport. Importantly for identifying the trigger
mechanism for elevated lipid catabolism, the expression of
many genes encoding myelin-related proteins or myelin-re

brain aging (Carney J M et al., Proc Natl Acad Sci USA 88:
3633-6 (1991), Hensley K et al., Ann N YAcad Sci 786:
120-34 (1996), Bickford P C et al., Brain Res 866: 211-7
(2000), Lee C K, et al. Nat Genet 25: 294-7 (2000), Jiang C H
et al., Proc NaZlAcad Sci USA 98: 1930-4 (2001)), We also

lated transcription factors on the microarray Was increased

found increased expression for molecules important in

catabolism, Were upregulated.

With aging (and several also Were correlated With cognitive

defense against oxidative stress (GST, GSTa1) (TABLE 1B).

impairment) (TABLE 1B). These observations strongly sug

One potentially key neW ?nding here, as noted above, Was
that DHPR Was upregulated With aging and correlated With

gest that a major increase in myelin synthesis programs devel

cognitive decline (TABLE 1B). Its product, tetrahydrobiop

oped With aging. This interpretation is also supported by the
upregulation of multiple genes important in lipogenesis for
cholesterol biosynthesis (Add 1/SREBP1), and the packag
ing/transport of cholesterol esters and other complex lipids
(ApoD, LCAT, etc.) (TABLE 1B). Recent studies have shoWn
that stimulation of myelin synthesis programs in oligoden

terin, is also an essential cofactor for nitric oxide synthase

(Boyhan A, et al. Biochem J 323 (Pt 1) 131-9 (1997)).
Because oxyradicals formed from nitric oxide appear to play
a major role in in?ammatory neuronal damage (Bal-Price A
& BroWn G C, JNeurosci 21: 6480-91 (2001), Calingasan N

drocytes is associated With induction of genes for both myelin

Y & Gibson G E, Brain Res 885: 62-9 (2000)), this may be an

proteins and lipogenic pathWays (Nagarajan R et al., Neuron

important pathWay through Which the deleterious effects of
in?ammation are mediated in brain aging.

30 355-68 (2001)).

Cyloskeleton/Vesicles. Moreover, expression of genes

20

vesicles (actin related complex, rsec8, tubulin, and syntaxin
7) Was increased (TABLE 1B). These molecules are associ
ated With vesicle transport and fusion in neurons. In addition,
hoWever actin assembly proteins are also knoWn to play a

25

major role in myelin vesicle transport in oligodendrocytes
(Madison D L et al., JNeurochem 72: 988-98 (1999)). Given

the upregulation of myelin programs and the doWnregulation
of synaptic plasticity genes, therefore, the age-dependent
upregulation of genes linked to vesicle transport capacity

egory, TABLE 1B). In addition, We extended those observa

tions to shoW that genes for proteoglycans (TABLE 1B) and
other extracellular proteins (e. g., ?bronectin) that are compo

transport in oligodendrocytes. Further support for the vieW
that extensive oligodendrocyte activation and/or synthesis
occurs in hippocampal aging is provided by the observation

nents of astroglial scars also Were upregulated. These changes

may re?ect astroglial-mediated reorganiZation of the extra
35

FAH, PGD-S, etc.) (e.g., Labelle Y et al., Biochim Biophys
Acza 1180: 250-6 (1993)).
40

elevation of myelin degradation, We also found increased

expression of Cathepsin S and other genes encoding lysoso
mal enZymes (TABLE 1B). Cathepsin S is particularly impor
tant in the processing of antigenic myelin fragments.

cellular matrix, a process knoWn to be unfavorable for axonal

remodeling.

entially expressed in oligodendrocytes (e. g., myelin proteins,
Myelin also is normally degraded to free fatty acids
through the endosomal-lysosomal pathWay. Consistent With

(1992), Nichols N R et al., NeurobiolAging 14: 421-9 (1993),
Finch C E & Longo V D, Neuroin?ammalory Mechanisms in
Alzheinier's Disease. Basic and Clinical Research, 237-256
(2001)) and the present data con?rm extensive upregulation
ofgenes (Finch C E & TanZi R E Science 278: 407-11 (1997))

for glial markers (e.g., vimentin, GFAP-cytoskeleton cat

seems more likely to be associated With enhanced myelin

that many genes that Were upregulated With aging are prefer

Glial Markers. Astrocyte reactivity and astrocyte markers
are also Well recogniZed to increase in the aged rodent and
human hippocampus (Land?eld P W et al., Science 214:
581-4 (1981), Land?eld P W et al., JNeurobiol 23: 1247-60

related to actin assembly, transport or fusion of packaged

Signal Transduction. Several genes in calcium regulating
and G-protein-coupled signaling pathWays Were also identi
?ed (TABLE 1B). In particular, S100A1, Which modulated
Ca2+-induced Ca2+ release, and PI 4-kinase, Which acts to
produce IP3 Were upregulated. Several other S100-related
genes (e.g., S100A4 and P9K2; TABLE 3) Were also upregu
lated With aging but failed to meet the strict criteria set forth

45

Amino Acids. In contrast to enZymes for glucogenic amino

herein (FIG. 2).
Biosynthesis. Concomitantly, many ribosomal (groWth)

acids (TABLE 1A), expression Was upregulated for multiple

and protein processing genes Were upregulated (TABLE 1B).
The upregulated changes re?ect increased protein synthesis,

genes encoding enZymes related to the metabolism of the

turnover and phagocytosis associated With strongly elevated

ketogenic/glucogenic amino acids, tyrosine, phenylalanine
and tryptophan (e.g., DHPR, KAT, FAH, see, TABLE 1B).

biosynthetic processes in glial compartments (e.g., elevated
50

Catabolism of ketogenic amino acids yields either acetoac

myelin, MHC, proteoglycan synthesis).
Orchestrating Factors. Our data shoW that a number of

etate or one of its precursors (e.g., acetyl CoA), Which can be

transcriptional regulators and cytokines, including KZF-l,

used either for energy metabolism or lipogenesis. Upregula
tion of DHPR, Which catalyZes the formation of a critical

RoaZ and members of the NFI family (TABLE 1B) Were
upregulated and therefore, may be strong candidates for coor
dinating factors. Under some conditions, several of these

cofactor (tetrahydrobiopterin) for tyrosine and monoamine
synthesis, and concomitant upregulation of MAO-B (TABLE
3), together suggest elevated metabolism of tyrosine and tryp
tophan via greater monoamine turnover.

55

factors function as negative transcriptional regulators.
Relationship to Fold Change. The large majority of
microarray analyses to date have used fold-change criteria to
detect changes in expression. In addition to providing little

In?ammation/ Defense/ Immunity. There Was massive

upregulation of expression of genes encoding MHC class I
antigen presenting molecules, and numerous other in?amma

60

tory/immune proteins (TABLE 1B). Genes in the in?amma
tion category exhibited some of the most robust monotonic

changes With aging seen in our results using the method of the
invention (e.g., most Were signi?cant at the p<0.001 criterion
With 0.025 FDR) (TABLE 1B). Moreover, most Were

inversely correlated With cognitive function (FIG. 3B).

65

basis for statistical assessment (e.g., Miller R A, et al. J
Gerontol A Biol Sci Med Sci 56 B52-7 (2001)), hoWever,
fold-change criteria are relative insensitive. Among the 139
ACGs, most exhibited group mean fold changes betWeen the
Young and Aged groups of less than 1.5 (92), a feW shoWed
fold changes betWeen 1.5 and 2.0 (26), and only a handful of

genes exceeded 2-fold-change (20) (TABLES 1A and B).
Thus, feW of our results using the method of the invention

US 7,739,056 B2
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Would have been detected in the great majority of prior
microarray studies, in Which 1.7 to 2-fold change cutoffs are
commonly used as minimum criteria for identifying differ

ries of upregulated genes had 50% or higher both-task corre

lations: Signaling (5/ 7), In?ammation (14/20), Cytoskeleton/
Vesicle (3/6), Myelin related proteins (3/5), Amino acid/
transmitter metabolism (2/4), Transporters and carriers (3/ 5),
and GroWth, biosynthesis, maintenance (7/ 12). In the Signal

ences, and many changes are reported in the 3-4 fold range.
Further, the rank order correlation betWeen group mean fold
change and p values on the ANOVA for all aging-signi?cant

ing category, moreover, genes involved in intracellular Ca2+
release, S100A1 and PI3-K (TABLE 1B), Were correlated

genes, although signi?cant, Was modest according to Spear
man’s correlation test (Spearman’s 1:045, p<0.001).Armit
age P & Berry G, Statistical Methods in Medical Research,
2'” Edn., 200-205 (1987). This indicates that fold-change
accounted for only ~20% of the variance (r2) in the degree of

With both tasks.
Another Way to examine closeness of correlation speci?

cally With memory impairment is to correlate gene expression
With performance only in the aged group. This correlation

statistical signi?cance on the ANOVA. Some of our results

focuses on variation in the performance of aged animals and

detected With the enhanced sensitivity of statistical analysis

removes the overall age course pattern from contributing to

Were extremely subtle (e.g., 1.1 fold for the L28 and L29

the correlation With impairment. This correlation is indepen

ribosomal proteins, TABLE 1B). Despite this enhanced sen
sitivity, hoWever, numerous false negatives Were still

dent of the ANOVA for aging effects and an FDR also can be

calculated. Consequently, We tested each of the 139 primary
aging- and behaviorally-related genes for correlation With 24
hr memory performance on the OMT in the aged group. The

undoubtedly present in our data set.

Age Course of Gene Expression Changes. Using a design
With three age groups enabled us to classify genes and cat

egories according to their general patterns of age dependence

OMT Was selected over the SWM for this test as it had the
20

of change (FIGS. 4 and 5). Genes Were classi?ed by Whether
75% of the maximal change occurred betWeen theYoung and

course had considerably less poWer than across all three
groups (n:29) and the criterion for signi?cance Was set at

Mid-Aged groups (Yng to Mid), the Mid-Aged and Aged
groups (Mid to Aged), or theYoung and Aged groups (mono

tonic).

p<0.025.
25

Almost all categories comprising doWnregulated and cog
nitively correlated genes (TABLE 1A), exhibited their great
est change betWeen the Young and Mid-Aged points, and
many did not shoW much additional doWnregulation betWeen
the Mid-Aged and Aged groups (FIG. 4). This Was also true

performance on the OMT. The FDR for these genes Was 0.28.

TWo of the 3 doWnregulated ACGs Were accounted for by the

Synaptic Structural Plasticity category (Fez-1, agrin). For
30

gen). No other category had more than one, including Tran

of upregulated genes shoWed a monotonic age course of
35

Thus, by the criterion of correlation on both tasks, the

upregulated categories of In?ammation/immune, signaling
(particularly Ca2+ signaling), Cytoskeleton/Vesicle and
40

Amino Acid Metabolism Were ranked most highly. By the
criterion of correlation in the aged group only, the upregu

lated categories of Cytoskeleton/Vesicle (3/ 6), Biosynthesis
(3/ 12) and In?ammation (2/20), and the doWnregulated cat
egory of Synaptic Plasticity (2/7) Were ranked most highly.
45

mance. To determine Which pathWays Were most closely cor

related With memory performance, We calculated the percent
age of genes in each of our categories that Were correlated

signi?cantly (at p<0.025) With both memory tests. We rea

scription (NFl-A) and Protein processing and tra?icking

(Skd3).

bers of exceptions that exhibited >75% of their change

betWeen the Young and Mid-Aged groups (TABLE 1B).

upregulated genes, tWo of the 10 ACGs Were from In?amma

tion (MHC and CD59 antigen), three from Cytoskeleton/
Vesicle category (Vcp, rsec8 and p41-Arc), and three from
Growth/Biosynthesis (2 ribosomal proteins and CD24 anti

decreased With aging at p<0.025 (pie-chart inset, FIG. 4).
Conversely, by far the largest fraction of functional categories

Additionally, among all genes that shoWed signi?cant
upregulation With aging, the majority ?t the monotonic clas
si?cation (pie-chart inset, FIG. 5). Only a feW scattered genes
shoWed a predominantly Mid to Aged change pattern (e.g.,
FIGS. 4 and 5 pie-charts).
Strongest Correlations of PathWays With Memory Perfor

Only 3 (4.9%) of the doWnregulatedACGs, but 10 (12.2%)
of the upregulated ACGs Were correlated With Aged group

for the entire population of genes Whose expression

change that also began betWeen the Young and Mid-Aged
points but, in addition, continued betWeen the Mid-Aged and
Aged points (FIG. 5). HoWever, the Cytoskeletal and Tran
scriptional Regulator categories contained signi?cant num

greater dispersion of performance needed for correlation
analysis. The correlation tests in the aged group (n:10) of

Bene?ts of the Invention. One of the major problems asso
ciated With developing treatments for aging-dependent func
tional decline is the lack of good genomic biomarkers or
targets of brain aging needed for evaluating the e?icacy of
different treatments. Our ACGs, therefore, could serve as

50

excellent biomarkers of cognitive aging. Using microarrays

soned that each test measures aspects of memory but each test
also has its oWn error sources and confounding contributions

constructed to contain oligonucleotide sequences speci?c for
hybridization With and measurement of mRNAs of the iden

from non-cognitive performance factors. Therefore, genes

ti?ed ACGs, laboratory animals could be assessed for degree
of cognitive aging before, during and after treatment With a

that correlated With both tasks seem more likely to be asso

ciated With cognitive processes.
Because memory performance changed most betWeen the

55

compound. Treatments that sloWed or reversed the ACG pro

?le during aging might be highly promising for development

Mid-Aged andAged groups (FIG. 1), Whereas doWnregulated

as neW therapeutic approaches. Further, treatments that

genes changed little (FIG. 4) and upregulated genes contin

sloWed or reversed expression pro?les of particular genes in
our panel of biomarkers might reveal Which speci?c genes

ued to increase (FIG. 5) betWeen those groups, the pattern of
age course changes relative to cognitive performance Was
more similar for upregulated than for doWn-regulated genes.

60

Not surprisingly, therefore, more upregulated (52%) than
doWnregulated (44%) genes Were correlated With perfor
mance on both tasks. Three categories of doWnregulated
genes had 50% or higher both-task correlations: Adhesion

and extracellular matrix (3/5), Metabolism (8/10), and Pro
tein processing and tra?icking (3/ 5). Whereas seven catego

among the subset of ACGs are most critical for the age

dependent functional decline and, therefore, Would suggest
genes and gene products that should be targeted With high
priority for development of therapeutic interventions. The
same approach could be applied using our panel of unique
65

brain aging genes that are not speci?cally clustered With
cognition related genes, to evaluate and develop neW thera

pies and compounds for treatment of brain aging in general.
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The panel of ACGs identi?ed here can be used on a

(Univ. Chicago Press, Chicago, 1990); Austad, S N, Why We

microarray to perform diagnostic tests. Subjects suspected of
having accelerated brain aging or early age-related neurode
generative disease could provide a small brain biopsy sample

Age. What Science Is Discovering about the Body's Journey

Through Life (Indianapolis, Wiley, 1999)) or by catabolic

ject’s suitability for pharmacologic intervention.

hormonal processes (e.g., glucocorticoids, Porter N M &
Land?eld P W, Nature Neurosci 1: 3-4 (1998)). These
changes include reduced neuronal activity and induce a subtle

Based on the gene lists described above, investigators can
develop neW drugs or treatments aimed at altering the activity

neurons, the reduced anabolic capacity leads to diminished

for testing by microarray. This could then determine the sub

shift from anabolic to catabolic metabolism in neurons. In

capacity for protein biosynthesis and, in particular, for activ
ity-dependent neurite remodeling and synaptogenesis. Con

of one or more genes in the lists, or products encoded by those

genes, or targets of the products, With the goal of counteract

ing age-related cognitive impairment or brain aging in gen

comitantly, an increase in degradation of myelin and lipids
begins, perhaps triggered by reduced neural activity, or

eral.
A smaller subset of ACGs, speci?cally linked to some
process or system (e.g., to in?ammation, mitochondrial func

reduced oxidative phosphorylation and/or demand for an
alternative energy source, or by an immune process similar to

reversing aging and cognitive changes dependent on that set

multiple sclerosis, among other possibilities. The degenerat
ing myelin fragments are endocytosed in micro glia and astro
cytes, degraded by lysosomes and packaged into antigen

of genes or gene-impacted systems, either in experimental

presenting MHC molecules.

tests to develop neW compounds, or as diagnostic or thera

orchestrating cytokines and transcription factors that trigger

tion, or lipid metabolism, etc.), could be used in a microarray
to test e?icacy of a neW compound targeted to sloWing or

peutic guides.

20

Relevance to Human Brain Aging and AlZheimer’s Dis
ease. Normal human brain aging is associated With memory
dysfunction and appears to set the stage for AlZheimer’s

This

in turn activates

an in?ammatory reaction in the glia and possibly, in macroph
ages. The in?ammation further accelerates the phagocytosis

and degradation of myelin. As astrocytes hypertrophy, they
increase glycolytic metabolism and synthesiZe “glial scar”
proteins (e.g., ?bronectins, proteoglycans) that alter the

disease and other age-related neurodegenerative conditions.
It also shares many features With animal models of aging.
Land?eld P W et al., JNeurobiol 23: 1247-1260 (1992). Thus,
many of the memory-correlated gene expression pro?les seen
here in rats may have implications for genomic mechanisms
of human brain aging and/or AlZheimer’s disease. This vieW

25

is supported by several parallels betWeen processes identi?ed

30

extracellular matrix. In oligodendrocytes, lipogenic and
myelin synthesis programs are activated in response to the

ongoing demyelination and/or altered signaling pathWays. In
turn, remyelination may increase demand for lipid substrate

and thereby also accelerate demyelination. Thus, positive
feedback cycles betWeen demyelination and myelination and/

here and those seen in human aging or AlZheimer’s disease.

or betWeen demyelination and in?ammation, among other

For example, myelin abnormalities are also found extensively
in normal brain aging in humans (leukoaraiosis). These White

processes, might develop and further drive cellular dysho
meostasis. Eventually, the reduced synaptogenic capacity

matter changes in humans are also correlated With cognitive
dysfunction and become more severe in disease states. Fur

ther, cerebral metabolism begins to decline by mid-life in
humans, much as it apparently does in rats (FIG. 4). Of
particular note in light of our ?ndings on oxidative phospho
rylation and myelin turnover, mitochondrial diseases in
humans also can result directly in demyelination.
It is interesting, in vieW of the apparently altered lipid

35

unfavorable extracellular matrix and degradative in?amma
tory processes result in failure of cognitive processing. Addi
tionally, the ongoing catabolic processes erode neuronal

membranes and cytoskeletons, increase protein aggregation
and enhance vulnerability to neurodegenerative disease.
Accordingly, our results, in conjunction With this Working
40

model, point directly to potentially useful therapeutic inter
ventions and should, therefore, facilitate the design of such

future therapeutics.

metabolism seen here, that activity of the cholesterol ester

synthesiZing enZyme acyl CoAzcholesterol acyltransferase

The details of one or more embodiments of the invention

(ACAT) is elevated in AlZheimer’s disease and appears

are set forth in the accompanying description above.
Although any methods and materials similar or equivalent to
those described herein can be used in the practice or testing of
the present invention, the preferred methods and materials are
noW described. Other features, objects, and advantages of the
invention Will be apparent from the description and from the

directly coupled to amyloid production. ACAT has lipogenic

45

functions someWhat similar to those of LCAT, Which Was also

upregulated here (TABLE 1A). Moreover, activity of glyc
erol-3-phosphate dehydrogenase (GPDH) is elevated in asso
ciation With abnormal glucose metabolism in brains of

patients With DoWn’s syndrome. The gene encoding this gly
colytic enZyme Was also upregulated here (TABLE 1A).

50

Other processes found in human aging orAlZheimer’ s disease
brain for Which We found corollaries in gene expression
include, as noted, in?ammation, oxidative stress and elevated

claims. In the speci?cation and the appended claims, the
singular forms include plural referents unless the context
clearly dictates otherwise. Unless de?ned otherWise, all tech
nical and scienti?c terms used herein have the same meaning
as commonly understood by one of ordinary skill in the art to

if these parallels depend, at least in part, on similar mecha

Which this invention belongs. All patents and publications
cited in this speci?cation are incorporated by reference.

nisms, our results shoW that Widespread genomic regulatory
changes Would reasonably be expected to contribute to

fully illustrate the preferred embodiments of the invention.

KatII (kynurenine aminotransferase 2), among others. Thus,
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The folloWing EXAMPLES are presented in order to more

altered cerebral metabolism, lipid synthesis, neural activity
and myelination in human brain aging as Well.
Implications for a NeW Hypothesis of Brain Aging. Based

These examples should in no Way be construed as limiting the
60

EXAMPLE 1

on the functional implications of our results, as discussed

above, We provide a neW Working model of brain aging (FIG.
6). Early in adult life (i.e., before mid-life) a series of brain

changes begin, perhaps initiated by neW expression of genes
that exert deleterious late-life actions (e.g., “late genes”)
(Finch C E, Longevity, Senescence and the Genome, 37-42

scope of the invention, as de?ned by the appended claims.

Behavioral Results
65

Thirty animals in three age groups (n:10/group) Were
trained sequentially on tWo tasks, ?rst in the Morris spatial
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Water maze (SWM) and then in the object memory task

objects. More time spent exploring the novel object (higher

(OMT). Male Fischer 344 rats aged 4 months (Young, n:10),
13 months (Mid-Aged, n:10) and 24 months (Aged, n:10)

MI) is considered to re?ect greater memory retention for the

Were used. Overall, the training/testing lasted seven days, and
hippocampal tissue Was collected 24 hr later. Training or

In the OMT, Aged animals performed as Well as Young or
Mid-Aged on the 1 hr retention test (not shoWn), but there Was

testing occurred on each day except for the 2'” and 3rd days of
the seven-day sequence.

p<0.001, for the main effect of age) on the 24 hr test (FIG.

Methods used here for cognition assessment in the Morris
Spatial Water MaZe (SWM), a task sensitive to both hippoc

different from the Aged group, but not from one another

familiar object.
a signi?cant age-related decline in recall (1-Way ANOVA,
1B). At 24 hr, Young and Mid-Aged groups Were signi?cantly

(Young vs. Aged: p<0.001; Mid-Aged vs. Aged: p<0.05;
Young vs. Mid-Aged: N.S., Tukey’ s post-hoc test; Armitage P
& Berry G, Statistical Methods in Medical Research, 2'”
Edn., 200-205 (1987)).

ampal function and aging, have been described previously
Norris C M & Foster T C, Neurobiol Learn Mem 71, 194-206
(1999). Brie?y, rats Were trained in a black tank, 1.7 M in
diameter, ?lled With Water (27120 C.). Behavioral data Were
acquired With a Columbus Instruments tracking system. After
habituation to the pool, animals Were given cue training With
a visible platform (?ve blocks of three trials, maximum of 60

EXAMPLE 2

Gene Microarray Chip Results

sec/trial, 20 sec intertrial interval and a 15 min interval
betWeen blocks). Rats remained in home cages under Warm

air after each block. Cue training Was massed into a single day
and the criterion for learning Was ?nding the platform on 4 of
the last 6 trials. For all animals that met this criterion, spatial
discrimination training Was initiated three days later in Which
the escape platform Was hidden beneath the Water but
remained in the same location relative to the distal cues in the

room. Fifteen min folloWing the end of spatial training, a
1 -min duration free-sWim probe trial With the platform absent
Was administered, during Which crossings over the former
platform site (platform crossings) Were recorded to test acqui
sition, folloWed by a refresher training block. Retention for
platform location Was again tested 24-hr later using a second

Microarray analyses Were performed on hippocampal CA1
20

animals (one chip per animal), but one chip Was lost for
technical reasons, leaving a data set of 29 microarrays

(Young:9, Mid-Aged:10, Aged:10). For tissue preparation,
tWenty-four hours after completion of the OMT testing, ani
25

124 NaCl, 2 KCl, 1.25 KH2PO4, 2 MgSO4, 0.5 CaCl2, 26
30
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task. During acquisition, Aged animals performed more
poorly (longer latencies) than Mid-Aged or Young. In addi

protocol (Gibco BRL, #15596). One ml of TRlZol solution

sured by platform crossings (1-Way ANOVA, p<0.05), Was
40

analysis indicated that Young and Mid-Aged animals exhib
ited more platform crossings relative to Aged animals, but did
not differ from each other.

Methods used here for cognition assessment in the object
memory task OMT) have been described previously by Enna

NaHCO3, and 10 dextrose. Hippocampi Were removed and
the CA1 region from one hippocampus per animal Were dis
sected by hand under a stereomicroscope. The CA1 tissue
block from each animal Was placed in a microcentrifuge tube
and ?ash froZen in dry ice for RNA isolation.
For RNA isolation, total RNA Was isolated using the TRI
ZOl reagent and folloWing the manufacturer’s RNA isolation
Was added to each tube containing the froZen tissue block and
the tissue Was homogeniZed by 10 passages through an 181/2

tion, an aging-dependent decrease in 24 hr retention, mea

observed on the retention probe trial (FIG. 1A). Post hoc

mals Were anesthetiZed With CO2 gas and decapitated. The
brains Were rapidly removed and immersed in ice-cold, oxy

genated arti?cial cerebrospinal ?uid consisting of (in mM):

1-min free-sWim probe trial.
During cue training in the SWM, all animals Were able to
locate the visible escape platform according to our criteria
and therefore, Were trained on the hidden platform spatial

tissues from each of the same behaviorally characterized 30

G syringe needle. After centrifugation, the RNA Was precipi
tated from the aqueous layer, Washed and redissolved in
RNase-free Water. RNA concentration and the integrity of
RNA Were assessed by spectophotometry and gel electro
phoresis. The RNA samples Were stored at —800 C.

Gene expression analyses Were performed using the
45

ceurA & Delacour J, BehavBrain Res 31: 47-59. (1988). The
object memory task (OMT) is also both sensitive to hippoc
ampal function and affected by aging but is less dependent on
physical strength and endurance. On the afternoon of the ?nal

Affymetrix GeneChip System. The labeling of RNA samples,
rat GeneChip (RG-U34A) hybridiZation and array scanning
Were carried out according to the Affymetrix GeneChip

Expression Analysis Manual (r.4.0, 2000). Each animal’s
CA1 RNA Was processed and run on a separate rat gene chip.

the OMT (63.5 cm><63 .5 cm). OMT training began 24 hr after

Brie?y, an average yield of 40 pg biotin-labeled cRNA target
Was obtained from 5 pg of total RNA from each CA1 sample,
of Which 20 ug cRNA Was applied to one chip. The hybrid

habituation and consisted of a 15-min acquisition session
during Which tWo 3 -dimensional objects Were placed at oppo
site sides of the cage, folloWed by tWo 15-min retention test

iZation Was run overnight in a rotating oven (Affymetrix) at
450 C. The chips Were then Washed and stained on a ?uidics
station (Affymetrix) and scanned at a resolution of 3 pm in a

spatial maZe probe trial, animals Were administered a habitu
ation session (15-min) in the empty mesh cage to be used for

50
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confocal scanner (Agilent Affymetrix GeneArray Scanner).

sessions at 1 and 24 hr posttraining. During the acquisition
session, the cage contained tWo sample objects (A and B) and
the time spent actively exploring each object Was recorded.

Each U34A rat chip (Affymetrix, Santa Clara, Calif.) con

tained 8,799 transcript probe sets (gene representations).
Although the measured signal intensity for a transcript probe

After 1 hr, the rat Was reintroduced into the cage and the time

spent exploring a novel object, C, relative to the familiar
object, B, Was recorded. On the 24 hr test, familiar object A
Was reintroduced and object B Was replaced by a second novel
object, D. Objects Were randomiZed across individuals and

60

stability and other factors in addition to gene transcription can
affect mRNA content.

We used the microarray suite (MAS 4.0) softWare (Af

timed measures of exploration Were used to calculate a

memory index (Ml) as folloWs: Ml:(N—F)/T, Where N is time

set (Methods) re?ects mRNA content, it is referred to here as

“gene expression”. HoWever, it is Well recognized that mRNA

65

fymetrix) to calculate the overall noise of the image (the

spent exploring the novel object, F is time spent exploring the

amount of variation around the mean intensity, QraW) for

familiar object, and T is total time spent exploring the tWo

each array. Overall noise Was highly similar across arrays in

US 7,739,056 B2
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all 3 age groups (Young: 21.8111.55; MidAged: 21.2512.24;
Aged: 206612.06, N.S.). “All probe set scaling” Was used to

function (by Pearson’ s test; Armitage P & Berry G Statistical

Methods in Medical Research, 2”“ Edn., 200-205 (1987))

set overall intensities of different arrays to an arbitrary target

(see, FIG. 2).
Multiple Comparison Reduction Step. The expected false

central intensity of 1500. Thus, the average intensity of each
array Was adjusted to the 1500 value using a scaling factor

positives in a series of multiple comparisons (false positive

(SF). There Was no signi?cant difference in SF across ages

rate) are predicted to be a percentage of the total statistical

(Young: 1.5810.14; MidAged: 1.4610.20; Aged: 16310.16,
N.S.).

comparisons to be made, as de?ned by the p-value (i.e., tests
at p<0.05 Will on average generate 5% false positives).

The algorithm used to determine Presence/Absence is
listed in the Microarray Suite 4.0 Manual and is the basis
upon Which a particular transcript is determined to be reliably
detectable by a given probe set. Average difference scores, the

Accordingly, the absolute numbers of expected false positives
can be decreased simply by reducing the total transcript sets

average of the difference in expression intensity (ADEI) of
each probe pair Within a probe set, formed the basis for

relevant to the speci?c interests of the analysis.
Using this step of the method, We reduced the total tran
scripts to be tested in three phases. In the ?rst phase, We

determining expression (relative abundance) of transcripts,

that are tested in a microarray analysis. This can be done by
deleting all transcripts identi?ed a priori as not likely to be
5

and throughout the text the term “expression level” refers to

deleted quality control oligonucleotide sets (“control”, n:60)

the ADEI score. When comparing across appropriately nor

malized arrays, the larger the ADEI score, the greater the

relative expression for that particular message. HoWever,
ADEI scores are not comparable for relative expression levels

20

among different messages on the same chip, as there are
several other factors that can confound such an assessment

tides used to test for the appropriate behavior of the techno
logical system, rather than to measure expression levels of

biological interest.

(e. g., p. 356, Affymetrix Microarray Suite 4.0 User’s Guide).
The Presence/Absence calls andAverage Difference scores
for all probe sets on all 29 arrays Were then copied from the

and all gene transcripts (probe sets) rated “absent” by our
criteria. As used in this speci?cation, the term “quality control
oligonucleotides” are those oligonucleotides and polypep

25

Of the original 8,799 sets, 4,118 gene transcript sets Were
removed at this stage, leaving 4,681 transcript sets that Were

called “present” for further consideration (FIG. 2, step 1a). In

MAS pivot table to an Excel 9.0 (Microsoft, SR-1)Workbook.
From Within Excel, the folloWing data manipulations Were

the second phase, We deleted all “present” transcript sets

representing “expressed sequence tags” (ESTs), Which have

performed.

not yet been clearly linked to knoWn genes (FIG. 2, step 1b).

Min-Max. For the purposes of ?ltering (FIG. 2), each probe
set Was normalized according to the formula:

30

There Were 1,213 such ESTs rated “present” that We ?ltered

out in this phase, leaving 3,468 transcript sets for further
consideration. The third reduction phase Was based on our

interest in persistent aging-dependent changes re?ected in
35

tested by deleting sets in Which the difference betWeen the
Young and the Aged group did not comprise at least 75% of
the maximum normalized difference among groups (i.e., in

Where x is ADEI score, Xmin is the mean for the age group
With the loWest ADEI score, and Ymax is the mean for the age
group With the largest ADEI score. Thus, normalized mean

values varied betWeen 0 (loWest) and 1 (highest) for each
probe set.
Standardization (Z-score): For the purpose of obtaining the
mathematical means Within functional categories and graph
ing, the data Was normalized using the Z-score method:

Which age-related changes from the Young baseline values
40
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Where X is the mean, and SD(x) is the standard deviation of
ADEI across all age groups for an individual probe set.

Statistical Analysis. All statistical tests Were performed

using a combination Excel (Microsoft, version 9, SR-l) and

Sigma Stat (SPSS, version 2).

substantial differences betWeen the youngest and oldest
groups. We further decreased the total transcript sets to be

55

Were maximal in the Mid-Aged group, but then reversed

substantially (>25%) in the Aged group, possibly because of
random, compensatory or developmental factors). There
Were 1,483 sets removed by this criterion, retaining 1,985
probe sets of the original 8,799 for formal statistical testing
(FIG. 2; step 2). If the original 8,799 sets hadbeen tested at the
p<0.025 alpha level, ~420 false positives Would have been
expected. HoWever, by reducing the total number of sets to be
tested for statistical signi?cance (at p<0.025), We reduced the
absolute numbers of false positives expected from multiple
tests, to ~50 (5% of 1985).
Group Statistical Testing Step (ANOVA). In this second
main step of the algorithm, each of the remaining 1,985
transcript sets Was tested by 1-Way ANOVA for a signi?cant
effect of aging (at p§0.025) across the 3 age groups (n:9—
10/ group). Of the 1,985 tested sets, 233 Were found to change

signi?cantly With aging (observed total positives). As noted,
at p<0.025, approximately 2.5% (~50) of the 1,985 tested
should be signi?cant by chance alone (expected false posi

EXAMPLE 3

Multi-Step Gene Identi?cation Algorithm
60

The analytic algorithm of the invention, Which addresses
the bioinformatics issues noted above, comprise three main
steps aimed ?rst, at reducing the number of comparisons (to
manage type I error), second, at reliably detecting modest

aging differences With global statistical analyses (by
ANOVA), and third, at identifying aging-related expression
changes that Were quantitatively correlated With cognitive

tives). In order to estimate the proportion of false discoveries
anticipated among our 233 observed positives (i.e., the frac
tion of observed positives expected to be false), We used the
expected false positive value to calculate the false discovery
rate (FDR) (Benjamini et al., Behav Brain Res 125: 279-284

(2001)). For any multiple comparison, the false discovery rate
65

provides an empirical estimate of the anticipated chance error
rate among all positives detected. It is partly analogous to the
p value of statistical tests, in that the false discovery rate

